Table 1

CMBs and different antithrombotic regimens; data from randomised trials

Incident CMBs between different antithrombotic regimens
Study, yearPopulation, nProportion baseline CMBsIncident CMB
(experimental arm)
Incident CMB
(control arm)
Duration of follow-upStatistics
CASISP101 Non-cardioembolic IS, n=60239%Cilostazol
5.82% (17/292)
Aspirin
5.48% (17/310)
12–18 monthsNon-significant
PERFORM-MRI00102 IS and TIA, n=74635%Terutroban
16.3% (59/362)
Aspirin
10.7% (41/384)
24 monthsNon-significant
CHANCE106 Minor acute IS/high-risk TIA, n=12953%Aspirin/clopidogrel
31% (21/68)
Aspirin
28% (17/61)
90 daysOR 1.16 (95% CI 0.54 to 2.47), p=0.71
AVERROES-MRI00103 Atrial fibrillation, n=71110.5%Apixaban 5/2.5 mg
7.0% (26/377)
Aspirin
7.2% (24/334)
12 months0.92 (0.53–1.60)
COMPASS-MIND105 Advanced systemic atherosclerotic disease, n=144530.3%Rivaroxaban 2.5 mg twice daily/aspirin 7.5% (36/481)
Rivaroxaban 5 mg twice daily
7.1% (34/477)
Aspirin
5.1% (25/487)
24 monthsRivaroxaban 2.5 mg/aspirin versus aspirin 1.49 (0.88–2.52), p=0.141
Rivaroxaban 5 mg versus aspirin
1.40 (0.82–2.39), p=0.215
NAVIGATE-MIND, unpublishedESUS, n=72832%Rivaroxaban 15 mg once daily
~7%
Aspirin
~7%
11 months0.93 (0.52–1.64)
Interactions between antithrombotic regimens and baseline CMBs for clinical outcomes
Study, year Population, n Proportion baseline CMBs Treatment strategies Clinical outcome Duration of follow-up Interaction between CMBs and treatments
SPS3 Trial107 Lacunar infarcts, n=127830%Aspirin/clopidogrel versus aspirin aloneStroke recurrence3.3 yearsNo
Pinteraction=0.45
RESTART Trial MRI substudy109 ICH, n=25493%Antiplatelet therapy versus no antithrombotic therapyRecurrent ICH2 yearsNo
Pinteraction=0.41, 0.75, 0.85 for CMBs presence, number and location
PICASSO Trial110 IS and past history of ICH or ≥2 CMBs, n=151260%Cilostazol versus aspirinICH1.9 yearsYes
Pinteraction=0.011
NAVIGATE ESUS111 ESUS, n=369911%Rivaroxaban 15 mg once daily versus aspirinICH11 monthsNo
Pinteraction=0.97
  • CMB, cerebral microbleed; ESUS, embolic stroke of undetermined source; ICH, intracerebral haemorrhage; IS, ischaemic stroke; TIA, transient ischaemic attack.